Aldeyra Therapeutics, Inc. (ALDX)
NASDAQ: ALDX · IEX Real-Time Price · USD
3.450
+0.370 (12.01%)
Mar 28, 2024, 11:47 AM EDT - Market open
Aldeyra Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for ALDX stock have an average target of 11.5, with a low estimate of 8.00 and a high estimate of 15. The average target predicts an increase of 233.33% from the current stock price of 3.45.
Analyst Consensus: Strong Buy
* Price targets were last updated on Oct 17, 2023.
Analyst Ratings
The average analyst rating for ALDX stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Oct '23 | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 |
---|---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
Buy | 0 | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Citigroup | Citigroup | Strong Buy Maintains $25 → $8 | Strong Buy | Maintains | $25 → $8 | +131.88% | Oct 17, 2023 |
Oppenheimer | Oppenheimer | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Oct 17, 2023 |
Oppenheimer | Oppenheimer | Buy Reiterates $14 | Buy | Reiterates | $14 | +305.80% | Aug 9, 2023 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +334.78% | Jun 30, 2023 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +334.78% | Jun 22, 2023 |
Financial Forecast
Revenue This Year
36.86M
Revenue Next Year
42.46M
from 36.86M
Increased by 15.19%
EPS This Year
-0.15
from -0.64
EPS Next Year
-0.69
from -0.15
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 99.8M | 70.7M | 261.0M | 404.9M | 348.6M |
Avg | 36.9M | 42.5M | 125.6M | 208.7M | 245.7M |
Low | n/a | n/a | 52.9M | 125.0M | 180.4M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | 91.7% | 514.8% | 222.5% | 67.1% |
Avg | - | 15.2% | 195.7% | 66.2% | 17.7% |
Low | - | - | 24.6% | -0.5% | -13.6% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 1.75 | 0.51 | 0.44 | 2.27 | 0.58 |
Avg | -0.15 | -0.69 | 0.14 | 1.11 | 0.56 |
Low | -1.09 | -1.31 | -0.15 | 0.02 | 0.54 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | 1,547.1% | -48.1% |
Avg | - | - | - | 707.4% | -49.5% |
Low | - | - | - | -85.8% | -51.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.